MX2021007548A - Adc con enlazadores multiplex de tiol. - Google Patents

Adc con enlazadores multiplex de tiol.

Info

Publication number
MX2021007548A
MX2021007548A MX2021007548A MX2021007548A MX2021007548A MX 2021007548 A MX2021007548 A MX 2021007548A MX 2021007548 A MX2021007548 A MX 2021007548A MX 2021007548 A MX2021007548 A MX 2021007548A MX 2021007548 A MX2021007548 A MX 2021007548A
Authority
MX
Mexico
Prior art keywords
adcs
multiplex
thiol
linkers
linking
Prior art date
Application number
MX2021007548A
Other languages
English (en)
Inventor
Scott Jeffrey
Kung- Pern Wang
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of MX2021007548A publication Critical patent/MX2021007548A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL

Abstract

La presente divulgación proporciona, entre otros, conjugados de anticuerpo y fármaco multiplexados con tiol (los TM-ADC) y conjuntos de enlace multiplex (los MLA) que comprenden múltiples fracciones de fármaco en un único conjunto de enlace.
MX2021007548A 2018-12-21 2019-12-20 Adc con enlazadores multiplex de tiol. MX2021007548A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862783707P 2018-12-21 2018-12-21
US201862783582P 2018-12-21 2018-12-21
PCT/US2019/068178 WO2020132655A1 (en) 2018-12-21 2019-12-20 Adcs with thiol multiplex linkers

Publications (1)

Publication Number Publication Date
MX2021007548A true MX2021007548A (es) 2021-12-10

Family

ID=71101991

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007548A MX2021007548A (es) 2018-12-21 2019-12-20 Adc con enlazadores multiplex de tiol.

Country Status (12)

Country Link
US (1) US20220040320A1 (es)
EP (1) EP3897734A4 (es)
JP (1) JP2022514348A (es)
KR (1) KR20210141918A (es)
CN (1) CN113543812A (es)
AU (1) AU2019403552A1 (es)
CA (1) CA3122316A1 (es)
IL (1) IL284147A (es)
MX (1) MX2021007548A (es)
SG (1) SG11202106122QA (es)
TW (1) TW202039008A (es)
WO (1) WO2020132655A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297167A (en) * 2020-04-10 2022-12-01 Seagen Inc Charging variant connectors
TW202400266A (zh) * 2022-05-18 2024-01-01 大陸商成都百利多特生物藥業有限責任公司 配體藥物偶聯物及其應用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821529B2 (en) * 2001-09-05 2004-11-23 Deanna Jean Nelson Oligo(ethylene glycoll)-terminated 1,2-dithiolanes and their conjugates useful for preparing self-assembled monolayers
CA2811667C (en) * 2010-09-29 2017-09-05 Philogen S.P.A. Thiazolidine linker for the conjugation of drugs to antibodies
US9981046B2 (en) * 2012-05-15 2018-05-29 Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. Drug-conjugates, conjugation methods, and uses thereof
CA2878733C (en) * 2012-07-12 2021-09-14 Hangzhou Dac Biotech Co., Ltd Conjugates of cell binding molecules with cytotoxic agents
EP3892294A1 (en) * 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions
TW201511774A (zh) * 2013-09-18 2015-04-01 Iner Aec Executive Yuan 放射性標誌之主動標靶性醫藥組合物及其用途
US11103593B2 (en) * 2013-10-15 2021-08-31 Seagen Inc. Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
US11135307B2 (en) * 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates

Also Published As

Publication number Publication date
IL284147A (en) 2021-08-31
CN113543812A (zh) 2021-10-22
JP2022514348A (ja) 2022-02-10
TW202039008A (zh) 2020-11-01
SG11202106122QA (en) 2021-07-29
WO2020132655A1 (en) 2020-06-25
EP3897734A4 (en) 2022-12-07
AU2019403552A1 (en) 2021-06-17
CA3122316A1 (en) 2020-06-25
KR20210141918A (ko) 2021-11-23
US20220040320A1 (en) 2022-02-10
EP3897734A1 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
USD873911S1 (en) Type font
EP3867250A4 (en) CONJUGATING LINKERS CONTAINING A 2,3-DIAMINOSUCCINYL GROUP
PH12020500398A1 (en) Antibody-pyrrolobenzodiazepine derivative conjugate
USD887487S1 (en) Typeface
USD913374S1 (en) Digital signage
WO2019236567A8 (en) Tumor microenvironment-activated drug-binder conjugates, and uses related thereto
HK1173169A1 (en) Dimercaptan terminated polythioether polymers and methods for making and using the same
USD867456S1 (en) Digital signage
ZA200705559B (en) IL-7 variants with reduced immunogenicity
TW200735162A (en) Ion sources, systems and methods
DE502007003072D1 (de) Gewebte Aortensinusprothese mit Bulbus
USD838028S1 (en) LED lamp
MX2021007548A (es) Adc con enlazadores multiplex de tiol.
USD955226S1 (en) Preserve can
MX2022013311A (es) Anticuerpo biespecifico anti-cd73-anti-pd-1 y uso del mismo.
WO2019092618A3 (en) Glp-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
EP4054648A4 (en) ANTIBODY-DRUG CONJUGATES TARGETING CLAUDINE 18.2
GT199800028S (es) Diseño de tableta.
USD877254S1 (en) Digital signage
USD849138S1 (en) Writing instrument
NI202000045S (es) Sistema de empaque
USD861792S1 (en) Digital sign
USD861791S1 (en) Digital sign
AU201815763S (en) Quick connection coupler
USD880592S1 (en) Digital signage